zirconium Zr 89 crefmirlimab berdoxam for Melanoma
This trial will test whether a new imaging tool can predict which cancer patients are likely to respond to immunotherapy.
- Merkel Cell Carcinoma
- Kidney Cancer
- Non-Small Cell Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
How many people are signing up to be a part of this clinical trial?
"The sponsor, ImaginAb, Inc., needs to recruit 80 eligible individuals from City of Hope (City of Hope National Medical Center and City of Hope Medical Center) in Duarte, Arkansas and CARTI Cancer Center in Little Rock, Washington."
Is zirconium Zr 89 crefmirlimab berdoxam a drug that has been cleared for use by the FDA?
"Zirconium Zr 89 crefmirlimab berdoxam is a medication that is currently being trialled in Phase 2 clinical trials. This means that while there is some data supporting its safety, there is none yet affirming its efficacy."
Are we still enrolling participants for this research?
"Yes, as reflected on clinicaltrials.gov, this study is still open to patient recruitment. The trial was initially posted on December 9th 2021 and edited for the 8th time on August 23rd, 2022."
What is the proposed outcome of this experiment?
"According to the trial sponsor, ImaginAb, Inc., the primary objective of this study is to measure Best overall response (BOR) using conventional imaging CT and/or MRI over a period of 24-27 weeks. Secondary objectives include Change in blood ALT levels (U/L), incidence of withdrawal from scanning protocol due to zirconium Zr 89 crefmirlimab berdoxam related AEs, and Change in blood BUN levels (mg/dL)."
How many research centers are conducting this clinical trial?
"At the moment, there are 5 sites where this trial is taking place. They are situated in Duarte, Little Rock and Irvine as well as a couple other places. It would be practical to choose the centre that is closest to you when enrolling to reduce travel time commitments."